Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


Resveratrol changes spermatogonial stem cells (SSCs) activity and ameliorates their loss in busulfan-induced infertile mouse.

Wu C, Zhang Y, Shen Q, Zhou Z, Liu W, Hua J.

Oncotarget. 2016 Dec 13;7(50):82085-82096. doi: 10.18632/oncotarget.12990.


Hydroxyurea: a new old therapy for Langerhans cell histiocytosis.

Zinn DJ, Grimes AB, Lin H, Eckstein O, Allen CE, McClain KL.

Blood. 2016 Nov 17;128(20):2462-2465. Epub 2016 Sep 29. No abstract available.


Characterization of leukemias with ETV6-ABL1 fusion.

Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Frederik Falkenburg JH, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J.

Haematologica. 2016 Sep;101(9):1082-93. doi: 10.3324/haematol.2016.144345. Epub 2016 May 26.


Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.


Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U.

Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. Epub 2015 Dec 10.


Rotation survival forest for right censored data.

Zhou L, Xu Q, Wang H.

PeerJ. 2015 Jun 11;3:e1009. doi: 10.7717/peerj.1009. eCollection 2015.


Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).

Zeidner JF, Gladstone DE, Zahurak M, Matsui WH, Gocke C, Jones RJ, Smith BD.

Leuk Res. 2014 Aug;38(8):886-90. doi: 10.1016/j.leukres.2014.05.012. Epub 2014 May 29.


Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea.

Jain P, Das VN, Ranjan A, Chaudhary R, Pandey K.

J Res Pharm Pract. 2013 Oct;2(4):156-61. doi: 10.4103/2279-042X.128145.


Interferon alfa versus interferon alfa plus cytarabine combination therapy for chronic myeloid leukemia: a meta-analysis of randomized controlled trials.

Chen R, Ma B, Yang K, Tian J, Liu Y, Zhao L.

Curr Ther Res Clin Exp. 2011 Aug;72(4):150-63. doi: 10.1016/j.curtheres.2011.06.002.


Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.

Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A, Hentschel S, Holleczek B, Kraywinkel K, Brenner H; GEKID Cancer Survival Working Group.

J Hematol Oncol. 2013 Sep 16;6(1):70. doi: 10.1186/1756-8722-6-70.


Tyrosine kinase inhibitors and interferon.

Dimou M, Panayiotidis P.

Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014006. doi: 10.4084/MJHID.2014.006. eCollection 2014 Jan 2. Review.


JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC, Silver RT.

Haematologica. 2013 Nov;98(11):e135-7. doi: 10.3324/haematol.2013.087742. No abstract available.


Automated synthesis and visualization of a chemotherapy treatment regimen network.

Warner J, Yang P, Alterovitz G.

Stud Health Technol Inform. 2013;192:62-6. Review.


Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.

von Bubnoff N 3rd.

Ther Adv Hematol. 2011 Apr;2(2):95-110. doi: 10.1177/2040620711402415.


Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J.

Leukemia. 2013 Apr;27(4):803-12. doi: 10.1038/leu.2012.313. Epub 2012 Nov 7. Review.


Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Baran Y, Saydam G.

J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16.


Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.

Lauseker M, Pfirrmann M, Hoffmann VS, Hasford J.

Haematologica. 2012 May;97(5):e14-5. doi: 10.3324/haematol.2011.061630. No abstract available.


Supplemental Content

Support Center